New pill for painful skin disease enters first human tests

NCT ID NCT07629336

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This first-in-human trial tests an oral drug called SAR447971 (KT-485) in healthy volunteers and people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study has three parts: single and multiple doses in healthy people, and multiple doses in HS patients. The main goal is to check safety and how the drug moves through the body. About 114 participants will take part, and results will guide future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR447971 (also known as KT-485) – an oral tablet
What this could lead to: If successful, this could lead to a new oral treatment option for hidradenitis suppurativa, a painful skin condition.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not yet testing effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS HIDRADENITIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Investigational Site Number: 5280001
RECRUITING

Leiden, 2333, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.